SGLT2抑制剂对T2DM患者心血管保护作用研究的进展  

Research progress of cardiovascular protection effect of SGLT2 inhibitors on T2DM patients

作　　者：李彩英 乔虹[1] LI Cai-ying;QIAO Hong(Department of Endocrinology and Metabolic Diseases,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院内分泌与代谢病科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2021年第5期629-632,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：研究发现钠-葡萄糖协同转运蛋白(SGLT)2抑制剂可显著降低心衰住院率。SGLT2抑制剂可降低心血管疾病危险因素、为心肌代谢提供能量、发挥SGLT1抑制作用,改善不良心脏结局等。本文就SGLT2抑制剂对2型糖尿病患者心血管保护作用研究的进展作一综述。Studies have found that sodium-glucose cotransporter(SGLT)2 inhibitor can significantly reduce incidence rate of hospitalization caused by heart failure.SGLT2 inhibitor can reduce risk factors of cardiovascular diseases,provide energy for myocardial metabolism,exert SGLT1 inhibition effect and improve adverse cardiac outcomes etc.The present article makes a review on research progress of cardiovascular protection effect of SGLT2 inhibitors on patients with type 2 diabetes mellitus.

关 键 词：心力衰竭 糖尿病 2型 协同转运子 

分 类 号：R541.6[医药卫生—心血管疾病]